BREAKTHROUGHS BLOG

May 31, 2016

One week of WHA, extensive debate, and two key R&D decisions

Matthew Robinson, MA
Policy and Advocacy Officer
GHTC
GHTC/Matthew Robinson
As happens every May, the World Health Organization’s (WHO) highest governing body, the World Health Assembly (WHA), met last week for its 69th annual meeting in Geneva, Switzerland. The agenda was the most packed in recent memory, consisting of more than 70 discussion items, many of which were controversial. As a result, the agenda did not conclude until the eleventh hour on Saturday, May 28. Despite the lengthy agenda and difficult conversations, the WHA made two key decisions impacting global health research and development (R&D). This post will focus on those agenda items then GHTC will publish a full report covering the entire WHA R&D debate the week of June 6.
 
In the meantime, you can watch a recording of the panel discussion and webinar hosted by GHTC and the Geneva Centre for Security Policy on May 23, which provides a broad overview of many of the R&D issues discussed at WHA.

Framework of engagement with non-State actors (FENSA)

Discussions around revising WHO’s policies and procedures for engaging with non-State actors (any group other than a member state) have been highly contentious. Advocates for the proposed framework have argued that WHO needs to insulate its normative functions from undue influence by outside groups, while others have argued that the unintended consequences of the pre-WHA draft framework could be dramatic for some of WHO’s partners by inappropriately categorizing some partnerships as commercial entities. The intensive negotiation process at WHA resulted in a compromise decision that addresses concerns previously discussed by GHTC regarding FENSA’s impact on product development partnerships, while also maintaining some of the more stringent restrictions on how WHO engages with for-profit companies. As such, FENSA will move forward into implementation with the following key adjustments:

 

  1. Assessments of any proposed engagement with non-State actors will be guided by an implementation guide prepared by the WHO Director-General, which lays out clear criteria and guidelines.
  2. Evaluation of new engagements will be conducted by a specialized risk assessment staff to remove as much of the burden as possible from program staff.
  3. Ongoing or repetitive engagements can be classified as low-risk and subjected to a streamlined evaluation process, so long as a full risk assessment has been conducted on a substantively similar project in the past.
  4. The private sector is prohibited from providing staff secondments to WHO and is dramatically restricted in how it can provide in-kind or financial contributions. 

Consultative Expert Working Group on Research and Development: Financing and Coordination (CEWG)

The CEWG is a continuation of the Expert Working Group (EWG), which was convened more than a decade ago to chart how WHO could better support R&D for neglected diseases. This WHA marked an opportunity for the global health community to approve the plan set forth by the WHO Special Programme for Research and Training in Tropical Diseases (TDR) to create a pooled fund to support R&D and a global health R&D observatory to develop and recommend global research priorities. After extensive negotiations, the WHA’s decision calls on the WHO to: 

 

  1. Expedite the further development of a global health R&D observatory.
  2. Develop terms of reference and a costed work plan for the observatory for consideration at the 70th WHA.
  3. Develop an operational plan for a voluntary pooled fund for consideration at the 70th WHA.
  4. Advocate for sustainable funding for the new mechanisms.
  5. Convene a series of expert working groups to inform the new mechanisms’ policies and procedures.
In combination, these directives make clear the concern that many member states shared regarding TDR’s ability to raise the additional funding needed to support its ambitious proposals, as well as a desire to better understand how the observatory would prioritize research project recommendations across the global health R&D portfolio. Given the debate regarding these two items, the WHA declined to give it the green light at this year’s assembly, preferring instead to ask for more detailed operational proposals for consideration next year.
 
Given all of the unanswered questions on both CEWG and FENSA heading into WHA, it was important to see compromises come out of the discussion; both processes will go forward, but in a measured fashion to allow the development of concrete workplans and guidelines to shape their implementation. GHTC will continue following both processes closely, and looks forward to helping ensure that the concerns of the global health R&D community are front and center in both initiatives.
Posted in:
WHO
back